Protara Therapeutics, Inc. announced the pricing of its underwritten public offering of 13,043,479 shares of common stock at $5.75 per share, expected to raise $75 million. The offering is set to close on December 8, 2025, with proceeds funding the development of TARA-002 and other clinical programs. J.P. Morgan, TD Cowen, and Piper Sandler are joint book-running managers for the offering. The shares will be issued under an effective shelf registration statement on Form S-3. This press release does not constitute an offer to sell securities. Forward-looking statements in this release highlight the risks and uncertainties associated with the offering and Protara’s expectations.

Read more at GlobeNewswire: Protara Announces Pricing of $75 Million Public Offering